Pegihep Injection (PegInterferon Alfa 2B)

Pegihep Injection ()Peginterferon Alfa-2b — Strength/Concentration to Confirm contains Peginterferon alfa-2b; microgram strength and reconstituted concentration not provided. Historically used in combination regimens for chronic hepatitis C in selected patients; treatment suitability depends on current specialist assessment and the specific presentation. Peginterferon alfa-2b binds type I interferon receptors and induces antiviral proteins and immune signalling, reducing viral replication.

Pegylation prolongs systemic exposure compared with unmodified interferon. Before treatment, assess HCV RNA, prior therapy, cirrhosis status, hepatitis B markers, other medicines and relevant liver and kidney tests. Cure is generally assessed by undetectable HCV RNA at least 12 weeks after completion (SVR12). Viral clearance does not remove the need for liver cancer surveillance in patients with cirrhosis. Do not invent 80/100/120 microgram strength, mg/mL concentration, pen type, vial size or reconstitution volume. These require the Pegihep carton/insert.

The Pegihep injection comprises pegylated interferon and is prescribed for treating some viral infections such as chronic hepatitis B and chronic hepatitis C. It can be prescribed by a physician considering the patient's viral infection, liver disease, laboratory test results, and general health condition. The course of treatment and dose depend on an individual case.
Some indications for prescribing the medicine are:

• chronic hepatitis B;
  
• chronic hepatitis C, when necessary;
• control viral activity and reduce inflammation in the liver.

Pegihep must be taken only under the supervision of an experienced physician since interferon treatment can have severe side effects.

Pegihep Injection has an active ingredient, which is pegylated interferon alfa that helps in fighting various viral infections such as chronic hepatitis B and hepatitis C. Pegihep is effective as it increases the body’s immune responses to the virus. Upon injection, it increases immune system cell activation and reduces viral multiplication. It reduces the levels of viruses in the body, hence reducing inflammation of the liver. The therapy schedule is dependent on individual circumstances.

Peginterferon alfa-2b plus ribavirin improved sustained virologic response versus older interferon regimens in historical studies; modern oral DAA regimens are generally preferred where suitable. Evidence is not brand-specific. SVR12 is a standard efficacy endpoint in HCV studies; rates cannot be transferred to different genotypes, regimens or cirrhosis groups without qualification.

Pegihep is a medicine that might cause some side effects since it includes Peginterferon Alfa-2b. However, everyone may have different side effects, and some of them might get better during the adjustment period.
The common side effects include:

• Fevers and chills
  
• Headaches
  
• Fatigue or weakness
  
• Joint and muscle pain
  
• Nausea and vomiting
  
• Loss of appetite
  
• Reactions at injection site
  
• Dizziness
  
• Insomnia
  
• Mood swings or irritability
  
• Blood cell level changes​

The severe side effects should be treated immediately; they may include:

• ​Depression or mood swings
  
• Difficulties with breathing
  
• Bleeding problems
  
• Severe abdominal pain
  
• Signs of allergy

Pegihep must be used as directed by your healthcare provider.

Follow the exact manufacturer instructions for this product and prescribed regimen. Do not double doses. Contact the treating team promptly if a dose of Peginterferon Alfa-2b is missed or a course is interrupted; the correct response varies between daily direct-acting antivirals and weekly peginterferon injection.

CBC, liver tests, thyroid function, mental health, weight, HCV RNA and pregnancy precautions if ribavirin is used. Confirm treatment response with HCV RNA at least 12 weeks after the final dose.

• Molecule/regimen prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103949s5250lbl.pdf​
  
• AASLD-IDSA HCV Guidance: https://www.hcvguidelines.org/​
  
• WHO hepatitis C guidance: https://www.who.int/health-topics/hepatitis​
  
• Medical information only. Individual treatment and dose selection require specialist assessment. Https://cdn.who.int/media/docs/default-source/food-safety/publications/chapter5-dose-response.pdf.
  
• National library of medicine. Efficacy of Peginterferon Alfa-2b. https://pmc.ncbi.nlm.nih.gov/articles/PMC5421384/​